Beyondspring Inc (BYSI)
$2.13
Insights on Beyondspring Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 337.5K → 437.5K (in $), with an average increase of 22.9% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -9.24M → -6.36M (in $), with an average increase of 20.6% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 318.1%
Performance
- $2.10$2.38$2.13
1.41%
Downside
Day's Volatility :11.76%
Upside
10.5%
- $0.65$4.00$2.13
69.32%
Downside
52 Weeks Volatility :83.67%
Upside
46.75%
Returns
| Period | Beyondspring Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 149.4% | 0.5% | 0.0% |
6 Months | 114.15% | 11.7% | 0.0% |
1 Year | 134.36% | 6.2% | 2.2% |
3 Years | -78.63% | 13.5% | -23.0% |
Highlights
Market Capitalization | 90.9M |
Book Value | - $0.46 |
Earnings Per Share (EPS) | -0.71 |
PEG Ratio | 0.0 |
Wall Street Target Price | 1.25 |
Profit Margin | 0.0% |
Operating Margin TTM | -1541.03% |
Return On Assets TTM | -38.69% |
Return On Equity TTM | -310.48% |
Revenue TTM | 1.6M |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | 29.4% |
Gross Profit TTM | 1.4M |
EBITDA | -29.6M |
Diluted Eps TTM | -0.71 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | -0.47 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 41.31%
Technicals Summary
Sell
Neutral
Buy
Beyondspring Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Beyondspring Inc | -37.12% | 114.15% | 134.36% | -78.63% | -83.96% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Beyondspring Inc | NA | NA | 0.0 | 0.0 | -3.1 | -0.39 | NA | -0.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Beyondspring Inc | Buy | $90.9M | -83.96% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
Decheng Capital LLC
12.71%BlackRock Inc
0.57%Group One Trading, LP
0.15%Capstone Capital Wealth Advisors
0.13%Acadian Asset Management LLC
0.09%State Street Corporation
0.08%
Corporate Announcements
Beyondspring Inc Earnings
Beyondspring Inc’s price-to-earnings ratio stands at None
Read More
Company Information
beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers
Organization | Beyondspring Inc |
Employees | 73 |
CEO | Dr. Lan Huang Ph.D. |
Industry | Health Technology |
